RHAMM-Target Peptides Inhibit Proliferation and Viability of Cancer Cells

Abstract

The incidence of cancer in the world is growing exponentially. Therefore, the search for targeted cancer therapy methods is the most urgent and actively developing the biomedicine field. This work is devoted to studying RHAMM-target peptides' effect on the proliferation and viability of ovarian cancer, prostate cancer, breast carcinoma, and adenocarcinoma of the breast duct cells. Cell proliferation was examined by a BrdU-based proliferation assay. Cell viability was assayed by the fluorescence method. It has been established that RHAMM-target peptides at a concentration of 2х10-7 M inhibited on ~ 55 % proliferation of MDA-MB-231 cells, on ~ 85 % proliferation of PC3m-LN4, and ~ 50 % proliferation of SKOV3 cells for 24 h. The results showed that the peptides inhibited the viability of ovarian cancer cells. In particular, peptide EEDFGEEAEEEA inhibited ovarian cancer cells' viability by 54%, peptide VEGEGEEGEEY by 63%, and peptide FTEAESNMNDLV by 57%. RHAMM-target peptides did not affect fibroblasts (non-tumor cells) and fibroblasts RHAMM(-/-). This work showed that RHAMM-target peptides at low concentrations of inhibited cancer cells' proliferation and viability. This effect was RHAMM mediated. RHAMM-target peptides are promising candidates for anti-cancer drugs.